Welcome to our dedicated page for Align Technology SEC filings (Ticker: ALGN), a comprehensive resource for investors and traders seeking official regulatory documents including 10-K annual reports, 10-Q quarterly earnings, 8-K material events, and insider trading forms.
The Align Technology, Inc. (NASDAQ: ALGN) SEC filings page on Stock Titan provides direct access to the company’s regulatory disclosures as filed with the U.S. Securities and Exchange Commission. As a global medical device manufacturer focused on the Invisalign® System of clear aligners, iTero™ intraoral scanners, and exocad™ CAD/CAM software, Align uses its SEC filings to report financial performance, governance changes, and other material events.
Investors can use this page to review current reports on Form 8-K, which in the provided examples include announcements of quarterly financial results and updates on executive and board changes. These filings often reference detailed press releases that discuss revenues, clear aligner case volumes, imaging systems and CAD/CAM services revenues, operating margins, restructuring charges, stock repurchases, and business outlook.
In addition to 8-Ks, users can expect to find annual reports on Form 10-K and quarterly reports on Form 10-Q (when available), which typically contain audited or reviewed financial statements, segment information, risk factors, and management’s discussion and analysis. For a company like Align in the medical device and digital dentistry space, these periodic reports are key sources for understanding trends in clear aligner volumes, adoption of iTero scanners and exocad software, and regional performance.
Stock Titan enhances the filings view with AI-powered summaries that explain complex sections of lengthy documents, helping users quickly identify items such as restructuring disclosures, research and development discussion, or references to intellectual property and legal proceedings. The page also surfaces insider transaction filings on Form 4 when available, allowing users to track reported purchases or sales of ALGN shares by directors and officers. Together, these tools help investors and researchers navigate Align Technology’s regulatory history and ongoing reporting obligations more efficiently.
Align Technology Inc ownership disclosure: Vanguard Capital Management reports beneficial ownership of 4,975,820 shares of Align Technology common stock, representing 6.94% of the class. The filing states Vanguard has sole dispositive power over 4,975,820 shares and sole voting power for 586,701 shares. The filing attributes holdings to Vanguard Capital Management and specified Vanguard affiliates and was signed by the Head of Global Fund Administration.
Align Technology reported solid first quarter 2026 results with growth in clear aligners and reaffirmed its full‑year outlook. Q1’26 net revenues were $1,040.1 million, up 6.2% year-over-year, driven mainly by Clear Aligner revenues of $856.0 million and record Invisalign shipments of 685.7 thousand cases.
GAAP gross margin was 70.8% and GAAP operating margin was 13.6%, while non‑GAAP gross and operating margins were 71.8% and 21.5%, respectively. GAAP diluted EPS was $1.57 and non‑GAAP diluted EPS was $2.58. The company completed a previously announced $200 million repurchase and plans to repurchase up to another $200 million of stock while reaffirming 2026 revenue growth guidance of 3% to 4% year-over-year.
Align Technology executive Jaime Holte Richardson filed an initial ownership report showing a mix of common shares and equity awards. She holds 937 shares of common stock, plus multiple grants of restricted stock units and market stock units that can convert into common shares at a nominal $0.0001 per-share exercise price.
The RSU awards cover 290, 579, 1,101 and 2,746 underlying shares that vest annually on grant anniversaries between February 20, 2027 and February 20, 2029. A separate market stock unit grant covers 5,576 target shares, with up to 250% of that amount eligible to vest based on performance at the end of a three-year performance period.
Align Technology is asking stockholders to vote at its virtual 2026 annual meeting on four items: electing ten directors, an advisory approval of executive pay, ratifying PricewaterhouseCoopers as auditor, and ratifying a special meeting bylaw that lets 25% holders call special meetings.
In 2025, Align generated $4.0 billion in revenue, including $3.2 billion from clear aligners and $789.6 million from systems and services. The company highlights global expansion, nearly 22 million Invisalign patients treated and 295,000 active trained practitioners, along with a pay program where 91% of the CEO’s target compensation is performance-based and recent reductions in his long‑term incentive targets. The proxy also emphasizes strong governance, stockholder rights, sustainability initiatives, and extensive human capital and community programs.
Align Technology, Inc. presents its 2026 Proxy Statement, highlighting 2025 business results, governance practices, and proposals for the May 20, 2026 virtual annual meeting (record date: March 23, 2026). Management reports $4.0 billion in 2025 net revenues: $3.2 billion from Clear Aligners and $789.6 million from Systems and Services. Align reached its 22 millionth Invisalign patient milestone and reported ~295,000 active Invisalign‑trained practitioners globally.
The statement summarizes strategic priorities—international expansion, GP engagement, adoption of the Align Digital Platform, iTero and exocad growth, AI-enabled ClinCheck enhancements, pilot direct printing with limited releases in 2026—and governance actions, including Board refreshment to ten directors, strengthened stockholder rights, and executive compensation changes (notably CEO realizable pay and reductions to target long‑term incentive values). Proposals ask stockholders to elect ten directors and ratify PwC as auditor and a special meeting bylaw provision.
Align Technology Inc receives an amended Schedule 13G filing from The Vanguard Group reporting 0 shares beneficially owned (0%) as of 03/13/2026. The filing states Vanguard completed an internal realignment on 01/12/2026 and certain subsidiaries will report ownership separately in reliance on SEC Release No. 34-39538.
The filing lists zero voting and dispositive power for Vanguard and is signed by Ashley Grim, Head of Global Fund Administration on 03/26/2026.
Align Technology, Inc. outlines its business model as a global medical device company focused on Invisalign clear aligners, iTero intraoral scanners and exocad CAD/CAM software, all connected through its integrated Digital Platform.
The company has two segments: Clear Aligner, which generated about 80% of worldwide net revenues in 2025, and Imaging Systems and CAD/CAM Services, which contributed the remaining 20%. Over 22 million patients have been treated with the Invisalign System, and Align estimates roughly 600 million people globally could benefit from malocclusion treatment, while only about 22 million start orthodontic treatment each year.
Align highlights ongoing innovation, including SmartTrack, SmartForce and SmartStage technologies, new iTero Lumina scanners and AI-driven tools like Align X-ray Insights and Invisalign Outcome Simulator Pro. The company is expanding internationally, deepening relationships with general practitioners and dental support organizations, and investing heavily in research, manufacturing resiliency and human capital across more than 20,000 employees worldwide.
Align Technology, Inc. updated its corporate bylaws after board approval on February 24, 2026. The amended and restated bylaws now require the board to call a special stockholder meeting if one or more stockholders properly request it and have continuously held at least 25% of the company’s outstanding common stock for at least one year before mailing the request.
The bylaws also add informational, timing, and other procedural requirements for such requests, and include additional clarifying, conforming, technical, and ministerial changes. The full amended bylaws are attached as an exhibit.
ALIGN TECHNOLOGY INC EVP and Chief Financial Officer John Morici reported multiple equity transactions involving restricted stock units, market stock units, and common stock. On February 20, 2026, he received a grant of 8,423 restricted stock units, which vest in four equal annual installments starting February 20, 2027.
He was also granted 17,102 market stock units, representing the target number of shares that may be issued; if performance exceeds target, up to 250% of this target may vest at the end of the three-year performance period. Several previously granted restricted stock units and a market stock unit vested and were converted into common shares through exercises coded as derivative conversions.
Following these transactions, Morici directly owned 16,085 shares of common stock, with 2,549 shares of common stock withheld at a price of $190.02 per share to cover tax obligations associated with the equity vesting.